No­vo Nordisk takes out the ax and aims at R&D, chop­ping 1,000 jobs

The di­a­betes mar­ket is a tough, com­pet­i­tive field dom­i­nat­ed by a few ma­jor play­ers. And to­day one of the most promi­nent in the bunch, No­vo Nordisk, says it will carve in­to its R&D or­ga­ni­za­tion as it slash­es 1,000 jobs in an ef­fort de­signed to pare ex­pens­es.

Out­side of R&D No­vo plans to trim head­quar­ters staff and some com­mer­cial groups as well. Al­to­geth­er it will cut 2% of its work­force. Half of those cuts are be­ing made in Den­mark with the ax falling on staffers be­tween now and the end of No­vem­ber.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER